WO2002066060A2 - Ultraschallgestützte transmembrane medikamentenapplikation in vivo - Google Patents
Ultraschallgestützte transmembrane medikamentenapplikation in vivo Download PDFInfo
- Publication number
- WO2002066060A2 WO2002066060A2 PCT/DE2002/000582 DE0200582W WO02066060A2 WO 2002066060 A2 WO2002066060 A2 WO 2002066060A2 DE 0200582 W DE0200582 W DE 0200582W WO 02066060 A2 WO02066060 A2 WO 02066060A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- ultrasound
- cavitation
- medicaments
- transmembrane
- assisted
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0028—Disruption, e.g. by heat or ultrasounds, sonophysical or sonochemical activation, e.g. thermosensitive or heat-sensitive liposomes, disruption of calculi with a medicinal preparation and ultrasounds
Definitions
- a method and a device are to be developed with which it is possible to first bring the medication to be administered into the body by separate injection in such a way that it is optional are aggregated on or within small vesicles or vesicles, which are then caused by an additional measure using ultrasound to deliver the medication to the cell membranes.
- the cavitation threshold which is locally reduced due to the presence of the small bubbles, permits the generation of further microcavitation in the immediate vicinity of the vessel walls, which increases the diffusion of the pharmacological or biological active substances into the target cells or into the target tissue association.
- the imaging ultrasound head is supplemented by a sound transducer which can be varied in amplitude and frequency and which, on account of its sound frequency and amplitude adapted to the bubble diameter, contributes to forced cavitation formation, or the frequency and the amplitude range of the imaging sound transducer are chosen such that they have this effect can exercise. The process is then observed and controlled under imaging control by the ultrasound head.
- FIG. 1 shows the basic structure and the procedure of the features essential to the invention.
- a tissue area 1 there is the vessel 2 with the vessel wall 3, into which the contrast medium 4, which consists of small bubbles 5 and the pharmacological or biological agents adhering to them or containing them, is administered.
- the contrast medium 4 which consists of small bubbles 5 and the pharmacological or biological agents adhering to them or containing them.
- part 6 of the bubbles 5 with the active substance adheres to the vessel wall 3.
- the ultrasound handpiece 7 now allows the process to be checked with the aid of the imaging ultrasound field 8.
- the handpiece 7 generates the therapeutic ultrasound field 8, which triggers the collapse of the vesicles 6 and induces increased microcavitation in the area in which the cavitation threshold is reduced by the vesicles 6 adhering to the vessel wall.
- the forces occurring during the collapse of the applied bubbles 6 of the contrast medium as well as the induced cavitation bubbles act on the adjacent tissue and the cell membrane and force the diffusion of the
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Surgical Instruments (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Ultra Sonic Daignosis Equipment (AREA)
Abstract
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10108798.5 | 2001-02-19 | ||
DE2001108798 DE10108798A1 (de) | 2001-02-19 | 2001-02-19 | Verfahren und Vorrichtung zur ultraschallgestützten transmembranen Medikamentenapplikation in vivo |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2002066060A2 true WO2002066060A2 (de) | 2002-08-29 |
WO2002066060A3 WO2002066060A3 (de) | 2003-02-06 |
Family
ID=7675272
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/DE2002/000582 WO2002066060A2 (de) | 2001-02-19 | 2002-02-18 | Ultraschallgestützte transmembrane medikamentenapplikation in vivo |
Country Status (2)
Country | Link |
---|---|
DE (1) | DE10108798A1 (de) |
WO (1) | WO2002066060A2 (de) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005075838A2 (en) * | 2004-02-09 | 2005-08-18 | Paul Scherrer Institut | Protection of surfaces against cavitation erosion |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997033474A1 (en) * | 1996-03-12 | 1997-09-18 | Board Of Regents Of The University Of Nebraska | Targeted site specific drug delivery compositions and method of use |
WO1997040679A1 (en) * | 1996-05-01 | 1997-11-06 | Imarx Pharmaceutical Corp. | Methods for delivering compounds into a cell |
WO1998051284A1 (en) * | 1997-05-13 | 1998-11-19 | Imarx Pharmaceutical Corp. | Novel acoustically active drug delivery systems |
WO2000002588A1 (en) * | 1998-07-13 | 2000-01-20 | The Board Of Regents Of The University Of Nebraska | Targeted site specific drug delivery compositions and method of use |
USRE36939E (en) * | 1991-03-22 | 2000-10-31 | Ekos Corporation | Composition for therapy of diseases with ultrasonic and pharmaceutical liquid composition containing the same |
WO2001026704A2 (en) * | 1999-10-12 | 2001-04-19 | Yehuda Yarmut | Targeted drug activation |
WO2002066597A1 (de) * | 2001-02-19 | 2002-08-29 | Dornier Medtech Systems Gmbh | Verfahren und vorrichtung zur ultraschallimpfung von biologischem zellmaterial |
-
2001
- 2001-02-19 DE DE2001108798 patent/DE10108798A1/de not_active Withdrawn
-
2002
- 2002-02-18 WO PCT/DE2002/000582 patent/WO2002066060A2/de not_active Application Discontinuation
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
USRE36939E (en) * | 1991-03-22 | 2000-10-31 | Ekos Corporation | Composition for therapy of diseases with ultrasonic and pharmaceutical liquid composition containing the same |
WO1997033474A1 (en) * | 1996-03-12 | 1997-09-18 | Board Of Regents Of The University Of Nebraska | Targeted site specific drug delivery compositions and method of use |
WO1997040679A1 (en) * | 1996-05-01 | 1997-11-06 | Imarx Pharmaceutical Corp. | Methods for delivering compounds into a cell |
WO1998051284A1 (en) * | 1997-05-13 | 1998-11-19 | Imarx Pharmaceutical Corp. | Novel acoustically active drug delivery systems |
WO2000002588A1 (en) * | 1998-07-13 | 2000-01-20 | The Board Of Regents Of The University Of Nebraska | Targeted site specific drug delivery compositions and method of use |
WO2001026704A2 (en) * | 1999-10-12 | 2001-04-19 | Yehuda Yarmut | Targeted drug activation |
WO2002066597A1 (de) * | 2001-02-19 | 2002-08-29 | Dornier Medtech Systems Gmbh | Verfahren und vorrichtung zur ultraschallimpfung von biologischem zellmaterial |
Non-Patent Citations (1)
Title |
---|
PORTER T R ET AL: "THE EFFECT OF MICROBUBBLE GAS COMPOSITION AND EXTERNAL ULTRASOUND FREQUENCY ON THE NON-INVASIVE ENHANCEMENT OF ANTISENSE OLIGONUCLEOTIDE DELIVERY TO THE VASCULAR WALL IN PIGS" CIRCULATION, AMERICAN HEART ASSOCIATION, DALLAS, TX, US, Bd. 96, Nr. 8, 21. Oktober 1997 (1997-10-21), Seiten L-401, XP000198974 ISSN: 0009-7322 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005075838A2 (en) * | 2004-02-09 | 2005-08-18 | Paul Scherrer Institut | Protection of surfaces against cavitation erosion |
WO2005075838A3 (en) * | 2004-02-09 | 2007-04-19 | Scherrer Inst Paul | Protection of surfaces against cavitation erosion |
Also Published As
Publication number | Publication date |
---|---|
WO2002066060A3 (de) | 2003-02-06 |
DE10108798A1 (de) | 2002-09-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE3839649C2 (de) | ||
DE69215722T3 (de) | Verstärker zur Ultraschalltherapie von Erkrankungen sowie diesen enthaltende flüssige Arzneimittelzusammensetzungen | |
E Konofagou et al. | Ultrasound-induced blood-brain barrier opening | |
EP0929347B1 (de) | Vorrichtung zur behandlung des herzens | |
Mason | Therapeutic ultrasound an overview | |
DE3808783C2 (de) | ||
DE602005004782T2 (de) | Transdermale arzneimittelabgabevorrichtung durch dehnung/lockerung | |
DE19752585B4 (de) | Vorrichtung und Verfahren zum Verkapseln von mikrobiellen, pflanzlichen und tierischen Zellen bzw. von biologischen und chemischen Substanzen | |
WO1989005160A1 (en) | Use of media containing bubbles in shock wave and ultrasonic therapy | |
WO2005011787A3 (en) | Apparatus and method for treating intravascular disease | |
JP2009506870A (ja) | 皮下組織を治療する方法 | |
DE10394286T5 (de) | Vorrichtung für verbesserte Schockwellen-Nierenzertrümmerung (SWL) unter Verwendung eines piezoelektrischen Ringanordnungs- (PEAA) Schockwellengenerators in Kombination mit einer primären Schockwellenquelle | |
DE4305660C2 (de) | Vorrichtung und Verfahren zur Steuerung der Größenverteilungen von Gas- oder Flüssigkeitsblasen in einem flüssigen Medium | |
WO2002066060A2 (de) | Ultraschallgestützte transmembrane medikamentenapplikation in vivo | |
DE3814743C2 (de) | Einrichtung zur Auflösung von Konkrementen in einer Körperhöhle | |
DE4414239A1 (de) | Vorrichtung zur Behandlung von krankhaften Zellen im lebenden Körper | |
DE19625164A1 (de) | Vorrichtung zum Auflösen von Thromben | |
EP3340970B1 (de) | Abscheidung von gelöstem sauerstoff über akustische tröpfchenverdampfung | |
WO1989010761A1 (en) | Process and device for inactivating viruses contained in a carrier medium | |
EP0282727A2 (de) | Verbesserung der Chemolyse von Konkrementen | |
WO2003030706A2 (de) | Einrichtung zum einführen in körperhohlorgane | |
DE4330958A1 (de) | Neue wirkstoffhaltige Mikropartikel, diese enthaltende Mittel, deren Verwendung zur ultraschallgesteuerten Freisetzung von Wirkstoffen sowie Verfahren zu deren Herstellung | |
DE10233293A1 (de) | Anordnung zur Verbesserung der Kavitations- und Wirkeigenschaften bei der Behandlung von Oberflächen biologischer Systeme | |
EP3501599A1 (de) | Vorrichtung zur stimulierung der lokalen regulation der mikrozirkulation, prophylaktisches oder therapeutisches verfahren sowie verwendung zur verbesserung repräsentativer merkmale des funktionszustandes der mikrozirkulation | |
EP2341957A1 (de) | Vorrichtung zur zerstörung von tumorzellen oder erregern im blutkreislauf |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): CA CN JP RU SG US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): CA CN JP RU SG US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |